JP2006502195A - 骨髄異形成症候群の処置用医薬の製造のための４−ピリジルメチル−フタラジン誘導体の使用 - Google Patents

骨髄異形成症候群の処置用医薬の製造のための４−ピリジルメチル−フタラジン誘導体の使用 Download PDF

Info

Publication number
JP2006502195A
JP2006502195A JP2004538994A JP2004538994A JP2006502195A JP 2006502195 A JP2006502195 A JP 2006502195A JP 2004538994 A JP2004538994 A JP 2004538994A JP 2004538994 A JP2004538994 A JP 2004538994A JP 2006502195 A JP2006502195 A JP 2006502195A
Authority
JP
Japan
Prior art keywords
pyridylmethyl
combination
vitamin
myelodysplastic syndrome
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004538994A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006502195A5 (enExample
Inventor
マーガレット・ハン・ドゥーガン
アラン・リスト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arizona's Public Universities
Original Assignee
Arizona's Public Universities
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arizona's Public Universities filed Critical Arizona's Public Universities
Publication of JP2006502195A publication Critical patent/JP2006502195A/ja
Publication of JP2006502195A5 publication Critical patent/JP2006502195A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2004538994A 2002-09-24 2003-09-23 骨髄異形成症候群の処置用医薬の製造のための４−ピリジルメチル−フタラジン誘導体の使用 Pending JP2006502195A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41317602P 2002-09-24 2002-09-24
PCT/EP2003/010578 WO2004028542A1 (en) 2002-09-24 2003-09-23 Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes

Publications (2)

Publication Number Publication Date
JP2006502195A true JP2006502195A (ja) 2006-01-19
JP2006502195A5 JP2006502195A5 (enExample) 2006-11-09

Family

ID=32043216

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004538994A Pending JP2006502195A (ja) 2002-09-24 2003-09-23 骨髄異形成症候群の処置用医薬の製造のための４−ピリジルメチル−フタラジン誘導体の使用

Country Status (22)

Country Link
US (1) US20060128716A1 (enExample)
EP (1) EP1545534B1 (enExample)
JP (1) JP2006502195A (enExample)
KR (1) KR20050074450A (enExample)
CN (1) CN100372535C (enExample)
AT (1) ATE359789T1 (enExample)
AU (1) AU2003299065B2 (enExample)
BR (1) BR0314647A (enExample)
CA (1) CA2499738A1 (enExample)
CR (1) CR7754A (enExample)
DE (1) DE60313344T2 (enExample)
EC (1) ECSP055700A (enExample)
ES (1) ES2285251T3 (enExample)
HR (1) HRP20050281A2 (enExample)
MX (1) MXPA05003161A (enExample)
NO (1) NO20051936L (enExample)
PL (1) PL374696A1 (enExample)
PT (1) PT1545534E (enExample)
RS (1) RS20050228A (enExample)
RU (1) RU2353364C2 (enExample)
WO (1) WO2004028542A1 (enExample)
ZA (1) ZA200502212B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE407683T1 (de) * 1997-10-15 2008-09-15 Polarx Biopharmaceuticals Inc Pharmazeutische zusammensetzungen enthaltend arsentrioxid zur behandlung von multiplen myelom
WO2007030582A2 (en) 2005-09-09 2007-03-15 Bristol-Myers Squibb Company Acyclic ikur inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001508800A (ja) * 1997-02-13 2001-07-03 ノバルティス アクチエンゲゼルシャフト 血管形成阻害活性を有するフタラジン

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7132458B2 (en) * 1994-08-10 2006-11-07 Chemaphor Inc. Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
RU2136308C1 (ru) * 1994-11-16 1999-09-10 Жемчугов Владислав Евгеньевич Стимулятор роста костно-мозговых клеток человека
CA2366857C (en) * 1999-03-30 2010-12-14 Novartis Ag Phthalazine derivatives for treating inflammatory diseases
AR025068A1 (es) * 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
CA2393252A1 (en) * 1999-12-06 2001-06-07 Paul Calabresi Use of methylol-containing compounds to treat tumors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001508800A (ja) * 1997-02-13 2001-07-03 ノバルティス アクチエンゲゼルシャフト 血管形成阻害活性を有するフタラジン

Also Published As

Publication number Publication date
AU2003299065B2 (en) 2006-10-26
US20060128716A1 (en) 2006-06-15
ATE359789T1 (de) 2007-05-15
ECSP055700A (es) 2005-08-11
CN1684684A (zh) 2005-10-19
NO20051936L (no) 2005-06-23
RU2005112711A (ru) 2006-02-27
CR7754A (es) 2005-12-02
DE60313344D1 (de) 2007-05-31
PL374696A1 (en) 2005-10-31
WO2004028542A1 (en) 2004-04-08
ZA200502212B (en) 2006-02-22
CN100372535C (zh) 2008-03-05
ES2285251T3 (es) 2007-11-16
DE60313344T2 (de) 2008-01-03
CA2499738A1 (en) 2004-04-08
HRP20050281A2 (en) 2006-07-31
BR0314647A (pt) 2005-08-02
EP1545534A1 (en) 2005-06-29
MXPA05003161A (es) 2005-09-12
EP1545534B1 (en) 2007-04-18
KR20050074450A (ko) 2005-07-18
RS20050228A (sr) 2007-08-03
AU2003299065A1 (en) 2004-04-19
RU2353364C2 (ru) 2009-04-27
PT1545534E (pt) 2007-06-22

Similar Documents

Publication Publication Date Title
EP1339458B1 (en) Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
JP2010159271A (ja) エポシロンを含有する組合せ剤およびその医薬上の使用
US20240075033A1 (en) Alk5 inhibitors for treating myelodysplastic syndrome
KR20040078123A (ko) 에포틸론 및 대사길항물질을 포함하는 조합물
AU2003299065B2 (en) Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes
KR20220124739A (ko) 암의 치료를 위한 병용 요법
AU2006271650B2 (en) Combination of a pyrimidylaminobenzamide and an MTOR kinase inhibitor
US20090233939A1 (en) Treatment of amm
JP2006502195A5 (enExample)
KR20240056487A (ko) 고형 종양을 치료하기 위한 약제학적 조성물
WO2023118062A1 (en) Combination of cisplatin and elimusertib for the treatment of pediatric liver cancers
US20090239872A1 (en) Treatment of mesothelioma
ZA200306404B (en) Combination comprising a signal transduction inhibitor and an epothilone derivative.
JP2006512360A (ja) ＶｏｎＨｉｐｐｅｌ−Ｌｉｎｄａｕ病の処置

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060921

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100216

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100706